We describe a single centre experience of 33 patients allografted for multiple myeloma, of which 28 received matched sibling marrow, one haploidentical family donor marrow and four matched but unrelated donor marrow. Median follow-up after transplant is 27 months, and 13 patients are currently alive. One out of four patients with an unrelated donor survives and 12 out of 28 (42.8%) with matched sibling donors. Four patients were unevaluable because of early death (Ͻday 21), and one patient experienced graft failure. The probability of overall survival is 35.7% at 3 years. The probability of disease-free survival is 39% at 3 years, and the probability of treatment-related mortality is 54% at 1 year. Acute GVHD developed in 26 (78.8%) patients and was responsible for six deaths. Twenty-four patients (72.7%) developed renal dysfunction and 22 (66.7%) developed hepatic dysfunction. Seventeen patients (51.5%) died of transplant-related problems in the first 150 days, and one at 6 months. Among the 13 survivors, none has experienced disease progression at a median follow-up of 27 months ( range 3-65 months). We conclude that since allogeneic bone marrow transplantation is the only potentially curative option in myeloma, it should be offered to younger patients early in the course of their disease, when procedure-related morbidity and mortality are likely to be at their lowest. Keywords: bone marrow allograft; sibling donor; matched unrelated donor; multiple myeloma Multiple myeloma (MM) is a malignant B cell disorder and the median survival is less than 3 years after conventional chemotherapy with melphalan and prednisolone, with only 3-5% of patients surviving beyond 10 years and the majority not attaining a durable complete remission (CR).
Multiple myeloma (MM) is a malignant B cell disorder and the median survival is less than 3 years after conventional chemotherapy with melphalan and prednisolone, with only 3-5% of patients surviving beyond 10 years and the majority not attaining a durable complete remission (CR). 1, 2 In our experience, infusional chemotherapy followed by autograft and interferon maintenance has resulted in very high complete response rates and better survival. [3] [4] [5] However, ultimately all patients are likely to relapse, the chances of relapse being as high as 50% in the first 2 years following the autograft.
Correspondence: Dr S Kulkarni, Dept Medical Oncology, Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK Received 30 July 1998; accepted 8 November 1998 Further chemotherapy and autograft may effect a response but the duration of this is usually shorter. Hence, standard treatments are very unlikely to achieve cure in myeloma. Various prognostic factors have been established to identify 'good risk' patients but they are not uniformly consistent. 6 Allogeneic bone marrow transplantation (BMT) is not considered routinely for most patients because the median age at diagnosis is greater than 55 years, and sibling donors are available in only 25% of cases. However, it may be an option for the 15-20% of patients who are below the age of 50 years of age at the time of diagnosis and is theoretically a better treatment option because the donor marrow is not contaminated with tumour cells. 7, 8 and a graft-versus-myeloma effect may exist. However, this approach has not resulted in better disease-free or overall survival because of the high treatment-related mortality associated with allograft procedures. 9, 10 To date, more than 500 cases of myeloma treated with allogeneic BMT have been reported world wide. [11] [12] [13] [14] [15] [16] We report our single centre experience of allogeneic BMT in myeloma and attempt to further define factors which may predict for an improved outcome.
Materials and methods
The prospectively maintained database at the Royal Marsden hospital was used to identify patients with multiple myeloma allografted between August 1981 and March 1998. Patient characteristics are shown in Tables 1 and 2 . Thirty-three patients with myeloma were transplanted using either an HLA matched sibling donor (n ϭ 28), a mismatched family member (n ϭ 1) or a matched but unrelated donor (n ϭ 4). Diagnosis and staging of the disease were carried out using the Durie and Salmon criteria. 17 Patients were considered for allograft if they had a suitable donor, a performance status of at least 2, and a serum creatinine below 200 mol/l. All patients received combination chemotherapy after diagnosis in an attempt to induce complete remission. Previous treatments are shown in Table 1 . Nineteen patients (57.6%) had received chemotherapy alone, and 14 (42.4%) had also been autografted with highdose melphalan (200 mg/m 2 ) as conditioning. Thirteen patients had received interferon at some stage prior to their allograft. Local radiotherapy was administered to 21 patients. Thirteen patients had achieved complete remission (CR), 10 partial remission (PR) and 10 had had no response to previous therapy. At the time of transplant, five patients were in CR, three in PR and 25 had progressive or resistant disease. The serum creatinine was less than 140 mol/l in 31 patients (93.9%). ␤2 microglobulin, measured in a total of 28 patients, was Ͻ2.5 in eight cases and Ͼ2.5 in 20.
Conditioning regimens
Twenty-eight patients (84.8%) were conditioned with total body irradiation (TBI) and chemotherapy, and five (18.2%) received chemotherapy alone as pre-transplant conditioning. Twenty-two patients received either melphalan (110 mg/m 2 ) with single fraction TBI at a dose of either 10.5 Gy (n ϭ 10) or 9.5 Gy (n ϭ 12). Three patients received cyclophosphamide (60 mg/kg/day ϫ 2 days) and single fraction TBI 9.5 Gy (n ϭ 1) or 10.5 Gy (n ϭ 2). Five patients received busulphan (16 mg/kg over 4 days) with melphalan (110 mg/m 2 , n ϭ 2) or cyclophosphamide (60 mg/kg/day ϫ 2 days, n ϭ 3). Three patients received cyclophosphamide (60 mg/kg/day ϫ 2 days), melphalan (50 mg/m 2 ), Campath (10 mg/day ϫ 4 days) and fractionated TBI (12 Gy in 6 fractions) as conditioning. One patient was conditioned with melphalan (110 mg/m 2 ) and fractionated TBI (12 Gy in 6 fractions). Patients with unrelated donors were conditioned with fractionated TBI in addition to Campath and Cy/Melph or Bu/Cy ( Table 2) .
The source of haematopoietic support was bone marrow in 29 patients (87.8%), and G-CSF-mobilised peripheral blood stem cells in four (12.1%). Marrow/stem cells were infused immediately after the last dose of radiation. The day of marrow infusion was designated day 0.
GVHD prophylaxis
Cyclosporine (3 mg/kg/day i.v., or 12.5 mg/kg/day p.o.) and short-course methotrexate (15 mg/m 2 day 1 and 10 mg/m 2 days 3, 6, 11) were used in 29 (87.8%) patients and four (12.2%) patients received only cyclosporine. The dose of cyclosporine was tapered from day 60 at a rate of 5% (25-50 mg) per week and patients continued taking this agent for 180 days. Grading and staging of GVHD were according to the Seattle criteria. 18 Acute GVHD of more than grade II was treated with methylprednisone at a dose of 1 g/day for 3 days and then tapered or stopped according to response.
Supportive care
All patients were managed in single, positive pressure rooms with laminar airflow and HEPA filters. Prophylactic antibiotics were not used. No patients received prophylactic growth factors. Blood components were administered to maintain haemoglobin levels and platelets above 9 g/dl and 20 ϫ 10 9 /l, respectively. Patients with neutropenic sepsis were treated with broad-spectrum antibiotics and antifungals as necessary, according to standard hospital policy. Patients did not receive prophylactic ganciclovir. Renal impairment was defined as rise of serum creatinine Ͼ200 mol/l. Liver dysfunction was defined as ALT or AST levels Ͼ5 times the upper limit of normal and/or bilirubin Ͼ34 mol/l.
Statistical analysis
Data were analysed as of 1 October 1998. Graft failure was defined as failure to achieve an absolute neutrophil count (ANC) Ͼ0.5 ϫ 10 9 /l by day 28 post allograft. Response to treatment was evaluated using criteria previously described by Gore et al. 19 Survival analysis, relapse probability and treatment-related mortality were estimated using the method of Kaplan and Meier. 20 Overall survival was measured from the date of allograft to death, or last follow-up. Event-free survival (EFS) was measured from the date of 677 Table 3 Causes of death n % transplant to disease progression or death, or last followup without disease progression. For EFS, patients not responding to the allograft procedure were evaluated as failures. Early mortality was considered to be death within the first 100 days of transplant. Median time from diagnosis to allograft was 14 months (range 1-140). Twenty-six patients (78.8%) were heavily pre-treated and had received more than two lines of therapy prior to allograft.
Results

Haematopoietic recovery and response
Five patients did not achieve ANC Ͼ0.5 ϫ 10 9 /l (four died before day 21 post allograft and one had graft failure, 3.03%). Among the remaining 28 patients, the median time to achieve an ANC Ͼ0.5 ϫ 10 9 /l was 23 days (range 19-31), and for platelets to reach 50 ϫ 10 9 /l, 24 days (range 13-67). A total of 17 patients died of transplant-related problems within the first 150 days, and one at 6 months. Among the remaining patients, 16 patients, 12 (36.4%) achieved a complete response (four in continued CR), one (3%) had a partial response, and three (9%) had no response.
Toxicity
Toxicity of the procedure was high. All patients experienced neutropenic sepsis. Infection was directly responsible for death in eight patients. Acute GVHD developed in 26 (78.8%). In 10 patients GVHD grade was above II and was responsible for six deaths. Twenty-four patients (72.7%) developed renal dysfunction and 22 (66.7%) hepatic dysfunction. Renal function normalized in 12 patients. Both the patients who had renal impairment at the time of transplant conditioning developed renal dysfunction (one had normalization post allograft). Seventeen patients (51.5%) died of transplant-related problems in the first 150 days. Causes of death are listed in Table 3 .
Post-transplant complications are shown in Table 4 . One patient died at day 260 with herpes pneumonia. Among those patients surviving for more than 100 days, chronic GVHD developed in six (18.2%, all of limited extent). Performance status in the survivors is normal although two patients are only 3 months post transplant. 
Survival
The median follow-up is 27 months (range 3-65), and 13 patients are currently alive. The probability of overall survival is 35.7% at 3 years, the probability of disease-free survival is 39% at 3 years and the probability of treatmentrelated mortality is 54% at 1 year (Figures 1 and 2 ).
Disease progression
Among the 13 survivors (CR, 12; PR, 1), none has experienced disease progression at a median follow-up of 27 months (range 3-65). No patient received interferon maintenance post allograft. 21, 22 One out of four patients with an unrelated donor is alive, and 12 out of 28 (42.8%) with matched sibling donors are alive.
Prognostic variables
We attempted to analyse the effect of sex, age at transplant, previous therapy, response to previous therapy, stage at the time of graft, interval between diagnosis and allograft, type of conditioning, ␤2 microglobulin levels, dose of radiation, creatinine clearance, and previous autograft on the toxicity of the procedure. The 2 year EFS was significantly less in patients who had undergone an autograft procedure prior to their allograft than in those who underwent allografting as their first ablative procedure (16.7% vs 47.9%; P ϭ Time since 1st allograft (years) % probability of toxic death Figure 2 Treatment-related mortality. 0.019) (Figure 3 ). Patients with a creatinine clearance of Ͼ100 ml/min at the time of transplant had significantly better survivals than those with less than 100 ml/min (72.7% vs 21.8%; P ϭ 0.013) (Figure 4 ). There was a trend towards higher mortality with the 10.5 Gy radiation dose (8/13, 61.5%) as against the 9.5 Gy dose (5/11, 45.5%). There was also a trend towards higher mortality with more than a 1 year interval between diagnosis and allograft (13/19, 68.4%, vs 6/14, 43%). We found no relationship between any of the other variables and toxicity of the procedure.
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Discussion
Conventional treatment of myeloma with melphalan and prednisolone results in complete remissions in less than 10% of patients. Infusional chemotherapy (C-VAMP) followed by autograft and interferon maintenance results in complete responses in 80% of patients, but the majority of patients ultimately relapse. 4, 5 To improve results, tandem transplants have been tried. 10, 23 Outcome is reported to be better than after a single transplant, but relapse rates are still as high as 40%, a fact which is not surprising since circulating myeloma cells are always detectable even after complete responses, 7 making tumour cell contamination of autologous marrow or stem cells unavoidable.
The sensitivity of myeloma cells to chemotherapy and radiation and the possibility of using tumour-free donor marrow which may also convey an immunologic graft-versus-myeloma effect forms the rationale for allografting in this disease. 9, 24 Allografts cannot be offered to all patients because of age constraints and paucity of suitable donors. However, they have been used for myeloma since 1980 although few studies have been reported in the literature and the number of patients in each is small. The largest study was reported by the EBMT Registry and evaluated the role of allografting in 162 patients. 12, 25 A complete response was achieved in 44% of patients and the overall survival was 32% at 4 years. Treatment-related mortality was not reported, and the overall relapse rate was 45% at 5 years. Female sex, ␤2 microglobulin Ͻ2.5, stage I disease at diagnosis, minimal previous treatment and complete remission at the time of allograft were associated with a favourable prognosis.
Bensinger et al 11, 26 reported 80 patients allografted for myeloma. They had a high proportion of cases with refractory disease (71%) and the transplant-related mortality was 43% at 100 days. Overall and EFSs were 24% and 20%, respectively, at 4.5 years. Multivariate analysis showed that transplantation longer than 1 year from diagnosis, ␤2 microglobulin Ͼ2.5, male donor to female recipient and more than eight cycles of previous chemotherapy, were associated with a poor prognosis.
Our complete response rate of 37% is similar to that of these major studies. Even though the median follow-up is short, it is interesting that we have not observed any relapses in the survivors. As we did not use maintenance interferon post allograft in these patients, 22 it appears that an allograft-associated graft-versus-myeloma effect may be in operation. This may have been potentiated by the acute or chronic GVHD which developed in 28 of 33 patients, and was responsible for the death of six patients.
Mehta et al 16 recently compared allografting with autografting in patients who failed their first autograft. The response rate was higher with allografting but was associated with a significantly higher mortality (43% vs 10%). Interestingly, there was no plateau in the EFS even at 5 years, as patients continued to suffer late relapses after allograft.
Lokhorst et al 24 reported the use of donor leukocytes for immunotherapy in post-allograft relapse of myeloma and found them to be effective in 62% of patients. This response rate is as good as for chronic myeloid leukaemia (CML) where DLI is reported to afford the best results. 27, 28 Most of the patients in this series were heavily pretreated and higher mortality occurred in patients who had received an autograft, with its attendant high-dose melphalan conditioning, prior to the allograft. This suggests that transplant-related toxicity may be reduced if patients are transplanted as soon as possible after their initial cytoreductive therapy given at diagnosis, and if the more intensive chemoradiotherapy regimen is saved as preparation for the allograft, then this may result in an improved outcome. Timing the transplant for early in the course of the disease in patients at higher risk of poor outcome with conventional chemotherapy by virtue of age and other negative risk factors will avoid submitting good prognosis patients to undue risk.
Reducing allograft-associated toxicity is necessary and will have an overall beneficial effect. We have observed reduced toxicity with a reduced TBI dose. T cell depletion, which in turn should result in a reduced incidence of GVHD, has also been reported to reduce early transplantrelated mortality, but its influence on relapse rate is currently unknown. 29 In conclusion, allografting may be associated with true long-term disease-free survival in myeloma, although treatment-related mortality is high. Younger patients with good renal function should be offered the option of allografting early in the course of their disease. An autografting procedure should not be undertaken in this patient population since patients invariably go on to relapse and the toxicity from autograft conditioning appears to contribute to a poorer outcome when allogeneic BMT is subsequently undertaken.
